We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Collaboration will explore trans-arterial delivery of Imugene’s CF33 oncolytic virus utilizing RenovoRx’s TAMP therapy platform. TAMP is expected to enable localized, targeted delivery of CF33...
New clinical trial supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc.Avelumab (BAVENCIO®) to be provided to Imugene for Phase 2 clinical study in HER-2 positive gastric or...
The Collaboration will evaluate Eureka’s anti-CD19 ARTEMIS® T-cell therapy in combination with Imugene’s CD19-expressing oncolytic virus onCARlytics in solid tumours Potential to address lack of...
Imugene enhances portfolio with novel CD19-expressing oncolytic virus from City of Hope, a comprehensive cancer center in Los Angeles, California, to be developed in combination with CD19-CAR T...
FDA Investigational New Drug (IND) package Worldwide, exclusive licence with long patent life Phase 1 clinical trial anticipated to commence in 2020 Ex-Viralytics members part of project team...
Highlights: Biolife Science Qld Limited (Biolife) is a cancer immunotherapy company targeting HER-2 specific cancers, including gastric cancer and breast cancer The immunotherapy...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.012 | -25 | 0.048 | 0.048 | 0.035 | 21216346 | 0.04208065 | DE |
4 | -0.014 | -28 | 0.05 | 0.0525 | 0.035 | 17968028 | 0.04513235 | DE |
12 | -0.018 | -33.3333333333 | 0.054 | 0.081 | 0.035 | 23448330 | 0.05286784 | DE |
26 | -0.036 | -50 | 0.072 | 0.081 | 0.035 | 19596243 | 0.05507035 | DE |
52 | -0.052 | -59.0909090909 | 0.088 | 0.13 | 0.035 | 22839022 | 0.07828776 | DE |
156 | -0.514 | -93.4545454545 | 0.55 | 0.555 | 0.035 | 23124675 | 0.14686581 | DE |
260 | -0.017 | -32.0754716981 | 0.053 | 0.625 | 0.016 | 21666349 | 0.16097903 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions